RESPONSE 2: A phase 3b study evaluating the efficacy and safety of ruxolitinib in patients with hydroxyurea (HU)-resistant/intolerant polycythemia vera (PV) versus best available therapy (BAT).
Francesco Passamonti
Consultant or Advisory Role - Novartis (U)
Guray Saydam
No relevant relationships to disclose
Liberata Lim
Employment or Leadership Position - Novartis
Stock Ownership - Novartis (I)
Mahmudul H Khan
Employment or Leadership Position - Novartis
Stock Ownership - Novartis
Nadjat Mounedji
Employment or Leadership Position - Novartis
Martin Griesshammer
No relevant relationships to disclose